South Korea has given final approval for the use of the COVID-19 vaccine developed by Janssen, a subsidiary of Johnson and Johnson.
The Food and Drug Safety Ministry made the announcement on Wednesday, meaning South Korea now has three vaccines approved.
The Janssen product is a viral vector vaccine given in one dose, and in trials it's shown an efficacy rate of 66.9 percent.
It'll be used for people 18 and older.
Once they're delivered, doses will be stored at between minus 25 degrees and minus 15 degrees Celsius for up to 24 months.
South Korea has signed a deal to get doses for up to 6 million people, which are scheduled for roll-out in the third quarter of this year.